By Chris Wack
Hookipa Pharma Inc. said Wednesday that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with Gilead Sciences Inc.
The company said it completed and delivered a regulatory support package for Gilead's Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using Hookipa's arenaviral platform.
Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate. Hookipa is eligible to receive milestone payments based on the achievement of specified development, regulatory and commercial milestones up to a total of more than $190 million, and is also eligible to receive tiered royalties on net sales.
Hookipa shares were up 7% at 86 cents a share in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
01-04-23 0738ET